Thirty patients with widespread neoplastic disease have been treated with high doses of anticancer drugs. At the end of the treatment bone marrow previously drawn from the same patients and stored at -79 °C was reinfused. Different chemotherapeutic drugs were employed, mainly cyclophosphamide (17 cases) for a total dose of 100 mg/Kg, given during 10 days. Two patients died within a month because of toxic effects due to the treatment. In 13 cases a remarkable regression of the neoplastic lesions was observed, while in 10 cases the objective improvement was slight. Three patients are still clinically free of disease more than two years after treatment. The reinfusion of autologous bone marrow seems to favour the haematologic recovery and to avoid the more dangerous toxic effects of high doses of chemotherapy. The results so far obtained do not allow any conclusion on the definite therapeutic advantage of high dosage of anti-cancer drugs over the conventional doses, although remarkable results have been obtained in few patients.
Get full access to this article
View all access options for this article.
References
1.
AmbrusJ. L.AmbrusC. M.FeltzE. and StutzmanL.: Bone marrow transplantation in cancer chemotherapy.Blood, 19: 523, 1962.
2.
ArielI. M. and PackG. T.: Treatment of disseminated melanoma with phenylalanine mustard (melphalan) and autogenous bone marrow transplant.Surgery, 51: 583–591, 1962.
3.
BiermanH. R.KellyK. H. and MarshallG. J.: Tumor response to multi-lethal dose chemotherapy.Clin. Res. (New York), 10: 120, 1962.
4.
BiermanH. R.KellyK. H.MarshallG. J. and ByronR. L.Jr.: Protective effect of leukapheresis in man against large dose antineoplastic chemotherapy.Blood, 17: 303–313, 1961.
5.
CogginsP. R.EismanS. H.ElkinsW. L. and RavdinR. G.: Cyclophosphamide therapy in carcinoma of the breast and ovary. A comparative study of intermittent massive vs. continuous maintenance dosage regimens.Cancer Chemother. Rep., 15: 3–8, 1961.
6.
ConradM. E. and CrosbyW. H.: Massive nitrogen mustard therapy in Hodgkin's disease with protection of bone marrow by tourniquets.Blood, 16: 1089–1103, 1960.
7.
Di PietroS.: Effetti collaterali e tossicità nell'uomo dei chemioterapici antitumorali. Corso Superiore di Aggiornamento sulla Chemioterapia dei Tumori. Milano, 7–12 maggio 1962, pp. 123–148. Casa Editrice Ambrosiana, Milano, 1962.
8.
Di PietroS. e GennariL.: Successo terapeutico con ciclofosfamide in un caso di mesotelioma pleurico diffuso.Tumori, 49: 69–74, 1963.
9.
DunnigamM. G. and BrownA.: Autologous bone-marrow and large doses of cytotoxic drugs in the treatment of malignant disease.Lancet, 2: 477–479, 1963.
10.
FerrebeeJ. W.BillenD.UrsoJ. M.LuW. C.ThomasE. D. and CongdonC. C.: Preservation of radiation recovery factor in frozen marrow.Blood, 12: 1096–1100, 1957.
IrvineW. T.NoonC. F. and BastableJ. R. G.: Regional and total-body perfusion of malignant tumours with cytotoxic drugs.Lancet, 1: 1254–1261, 1962.
13.
IshibashiY.HattoriT.AbeY.IchikawaY. and MoriK.: Studies on bone marrow transfusion against acute bone marrow failure caused by agents administrated. Proc. 8th Congr.Int. Soc. Blood Transf., Tokyo, 1960(suppl. Bibl. Haematol.), 369–371, 1962.
14.
KempN. H. and AndersC. J.: Cyclophosphamide in disseminated malignant disease.Brit. Med. J., 2: 1516–1523, 1961.
15.
KempN. H. and AndersC. J.: Cyclophosphamide in disseminated malignant disease.Brit. Med. J., 1: 1145, 1962.
16.
LeoneL. A.ColbertM. P. and YorkC. L.: Prolonged intravenous infusion chemotherapy of advanced cancer. I. Combined therapy with nitrogen mustard + actinomycin D, Thiotepa + actinomycin D and thiotepa + actinomycin P2.Cancer Chemother. Rep., 15: 21–32, 1961.
17.
LochteH. J.Jr., KasaturaS.Karetzky, FerrebeeJ. W. and ThomasE. D.: Infusion of marrow in the mouse and dog after thiothepa.Blood, 21: 424–428, 1963.
18.
LouisJ.: Dose-response in cancer chemotherapy.Proc. Amer. Ass. Cancer Res., 6: 42, 1965.
19.
MannickJ. A.LochteH. L.AshleyC. A.ThomasE. D. and FerrebeeJ. W.: Autografts of bone marrow in dogs after lethal-total-body radiation.Blood, 15: 255–266, 1960.
20.
MathéG.: Transfusion et greffe de cellules myeloïdes chez l'homme.Biological problems of grafting. Vol. I, pag. 314. Ed. Univ. Liège, 1959.
21.
MillerE.SullivanR. D. and ChryssochoosT.: The clinical effects of mitomycin C by continuous intravenous administration.Cancer Chemother. Rep., 21: 129–135, 1962.
22.
Nissen-MeyerR. and HöstH.: A comparison between the hemathological side effects of cyclophosphamide and nitrogen mustard.Cancer Chemother. Rep., 9: 51–55, 1960.
23.
OlivaL. e StuartC.: Lo shock citostatico da somministrazione di ciclofosfamide nella cura di alcuni tumori maligni.Min. Med., 55: 332–336, 1964.
24.
OsswaldH.: Zur Behandlung transplantabler Tumoren mit cytotoxischen Verbindungen.Symposion über Krebsprobleme, Düsseldorf, 27–28 Juni, 1960, p. 128–136. Springer-Verlag, Berlin, 1961.
25.
PeggD. E.: A quantitative study of bone marrow grafting: implications for human bone marrow infusion.Brit. J. Cancer, 16: 400–416, 1962.
26.
PeggD. E.HumbleJ. G. and NewtonK. A.: The clinical application of bone marrow grafting.Brit. J. Cancer., 16: 417–435, 1962.
PricoloV. e Di PietroS.: Sull'azione terapeutica di alcuni derivati dell'azoiprite nei tumori maligni epiteliali e connettivali.Tumori, 37: 384–4001951.
29.
SloviterH. A. and TietzeR. M.: A method for preparing thawed erythocyteglicerol mixtures for transfusion.Am. J. Med. Sc., 231: 437–440, 1956.
